公开(公告)号：US20240109972A1

公开(公告)日：2024-04-04

申请号：US18038818

申请日：2021-12-07

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria JURE-KUNKEL ,  Manish GUPTA ,  Tahamtan AHMADI ,  Kathy AMIRI ,  Gaurav BAJAJ

IPC: C07K16/28 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505

Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.

公开(公告)号：US20240262924A1

公开(公告)日：2024-08-08

申请号：US18570257

申请日：2022-06-20

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria N. JURE-KUNKEL ,  Gaurav BAJAJ ,  Craig THALHAUSER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.

公开(公告)号：US20240327544A1

公开(公告)日：2024-10-03

申请号：US18579086

申请日：2022-07-13

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Sina FELLERMEIER-KOPF ,  Yali FU ,  Homer ADAMS, III ,  Gaurav BAJAJ ,  Brandon HIGGS ,  Mark FERESHTEH ,  Vanessa SPIRES ,  Jordan BLUM ,  Patricia GARRIDO CASTRO ,  Michelle NIEWOOD ,  Friederike GIESEKE ,  Karsten BECKMANN ,  Claudia PAULMANN ,  Ivan KUZMANOV ,  Esther Cornelia Wilhelmina BREIJ ,  Lars GUELEN ,  Jost NEIJSSEN ,  Bart-Jan DE KREUK ,  Richard HIBBERT ,  Janine SCHUURMAN ,  Aran Frank LABRIJN

IPC: C07K16/46 ,  A61K39/00

CPC classification number: C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/76

Abstract: The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20240174759A1

公开(公告)日：2024-05-30

申请号：US18549346

申请日：2022-03-09

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Yali FU ,  Homer ADAMS ,  Gaurav BAJAJ

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K9/0019 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565

Abstract: The present disclosure relates generally to the field of multispecific binding agents for use in therapy, in particular for use in treating cancer, wherein the binding agents bind to human CD40 and to human CD137.